drugset / Trial / NCT05681429

Accelerated Recovery Following Opioid-free Anaesthesia in Supratentorial Craniotomy

NCT05681429

RandomizedParallel-groupSingle-blindOther

Summary

Anaesthesia for craniotomy (open skull/brain) surgery focuses on maintaining blood supply to brain, avoiding factors that may lead to increased pressure in brain and aim for early neurological recovery. In recent decades, opioids have always been a mainstay for pain management and opioid-based anaesthesia (OBA). However, opioid use poses a significant number of adverse effects such as breathing depression, prolonged sedation, nausea and vomiting, itchiness, and many more. In view of this, recent studies on anaesthesia for craniotomy has noted a paradigm shift towards opioid-sparing or opioid-free anaesthesia (OFA) to prevent opioid-related adverse effects which might prolong patients' recovery. In order to guide anaesthesiologists' dosing of hypnotics and analgesics to provide appropriate depth of anaesthesia and adequate pain control, as well as to prevent under or overdosing, CONOX monitor is used during operation to measure depth of anaesthesia and painful stimulus. This clinical study will take place in neurosurgical operation theatres and neurosurgical intensive care unit (ICU) of University of Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia.

Timeline

Start
2023-01-01
Primary completion
2024-01-31
Completion
2024-01-31

Drugs

EvaluationDrugModalityDoseRoute
Background Acetaminophen Small molecule 1 g Intravenous
Background Dexmedetomidine Other / unclassified 0.2 ug/kg Intravenous
Background Dexmedetomidine Other / unclassified 0.7 ug/kg Intravenous
Background Lidocaine Other / unclassified 1.5 mg/kg Intravenous
Background Parecoxib Small molecule 40 mg Intravenous
Background Sevoflurane Other / unclassified 0.9 unknown Inhaled
Background Sevoflurane Other / unclassified 1 unknown Inhaled

Indications

No indication recorded.